597 results about "Cell toxicity" patented technology

The present invention is a method for determining the identity of the epitopes recognized by T-cells. The method consists of expressing an encoded library of candidate epitope sequences in a recipient reporter cell capable of providing a detectable signal upon cytotoxic attack from a single cognate T-cell followed by contacting the reporter cells with T-cells of interest. The reporter cells with a single indicating cytotoxic attack from a T-cell are isolated and then analyzed by next-generation sequencing in order to identify the epitope sequences. Specifically disclosed is a method in which a library of candidate epitope-encoding nucleic acids are expressed in cells which feature a membrane-bound major histocompatibility complex (MHC) protein, said library produced by transfection of plasmids featuring both a nucleotide encoding the candidate epitope and a nucleotide encoding a FRET-based fluorescent protein cleaved by granzyme.

The invention relates to the high degree of exchange Ca-A type zeolite hemostasis dressing and the preparation method and the purpose. The zeolite hemostasis dressing of the invention containing the zeolite has fast hemostasis speed, and has no bacterium, no pyrogen, no cell toxicity, no hypersensitive reaction and no skin irritation, the using is convenient and the cost is low.

The invention discloses a polyether-ether-ketone biomimetic artificial bone 3D printing manufacturing method, wherein the artificial bone can replace metal and has an excellent biocompatibility. The method comprises the following steps: first, collecting the bone tissue image data of the part, which is about to be implanted with an artificial bone, of a patient by using a medical instrument; secondly, establishing a three-dimensional digital model of the artificial bone on the basis of the collected data; thirdly, carrying out a format conversion on the three-dimensional digital model of artificial bone, inputting the converted file into a 3D printing system to manufacture the artificial bone; and finally carrying out cell toxicity tests, animal tests, and clinical tests. The invention utilizes a self-made polyether-ether-ketone 3D printing system to manufacture artificial bones, thus the time and cost for manufacturing moulds are saved, the manufacture period is shortened; at the same time, the shape of parts can be adjusted at any time according to the setting of the forming software; so that an crystalline polymer polyether-ether-ketone artificial bone, which has excellent biocompatibility, can be implanted into the human body, and has the advantages of high melting point, large viscosity, and bad fluidity, can be manufactured through the 3D printing method.

The present invention relates to a phenothiazinium compound of Formula (I): wherein: A and B each independently is in which R' and R'' each independently is a linear, branched or cyclic hydrocarbon group, or R' and R'' together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring; and where X<p-> is a counteranion and P is 1, 2 or 3; except for the compounds in which A and B are both either -N(CH3)2 or -N(CH2CH3)2 for use in a treatment that requires removal, deactivation or killing of unwanted tissues or cells. The invention also relates to compositions comprising the compounds of Formula I, to selected compounds of Formula I, use of the compounds of Formula I as medicaments and as a PDT agent or a photodiagnostic agent, a conjugate or composite formed between a compound of Formula I and a polymer; and to a method for sterilising fluids in which the fluid is passed over the conjugate or composite whilst it is illuminated. The compounds are biologically active photosensitisers which are strongly photocytotoxic and have application in the areas of photodynamic therapy (PDT), as well as for the diagnosis and detection of medical conditions and related uses in photochemical internalisation, in the production of cancer vaccines, in the treatment and prevention of microbial infections and in photodisinfection or photosterilisation.

The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and / or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and / or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and / or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.

A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which produces antimicrobial peptides that may be used in antimicrobial compositions and articles.

The invention relates to a copper sulfide / mesoporous silicon dioxide core-shell nano material as well as a preparation method and an application thereof. The chemical formula of the core-shell nano material is Cu9S5 / mSiO2-PEG. The preparation method comprises the following steps of: (1) raising the temperature of oleylamine under the protection of nitrogen; adding a mixed solution of copper dibutyldithiocarbamate and the oleylamine and dispersing the mixed solution into chloroform to prepare a D solution; (2) dissolving a surfactant into water; raising the temperature and adding the D solution to prepare an E solution; and (3) taking the E solution and adding ethanol; raising the temperature and adding an NaOH solution; immediately adding TEOS (Tetraethylorthosilicate) and reacting; adding PEG-silane; continually reacting and carrying out hydrothermal reaction; and adding into a scrubbing solution to centrifuge and wash to obtain the product. The copper sulfide / mesoporous silicon dioxide core-shell nano material is applied to near-infrared photo-thermal treatment, anti-cancer drugs, chemotherapy of tumors and infrared heat imaging. The nano material disclosed by the invention has very low cell toxicity and very high blood compatibility; and the united effects of thermal therapy and the chemotherapy are good.

The invention provides compositions and associated methods for the antisense treatment of genetic disorders, infections and various other medical conditions. In particular, embodiments of the present invention are directed to pharmaceutical compositions comprising a combination of an antisense oligonucleotide compound conjugated with a positively charged polymer (“ON-PCP”) and a negatively charged polymer. Pharmaceutical compositions in accordance with the present invention have demonstrated improved antisense efficiency and reductions in cell toxicity compared to compositions that contain an oligonucleotide compound conjugated with a positively charged polymer.

The present invention is based, at least in part on the discovery of therapeutic agents capable of preventing, inhibiting or modulating abnormal processing, misfolding or aggregation of protein. The therapeutic agents of the invention may prevent, inhibit or modulate the formation of inclusions. The therapeutic agents of the invention may also be capable of facilitating clearance and / or blocking the cellular toxicity of inclusions to treat or ameliorate disorders characterized by protein aggregation. Compounds which bind to structural motifs commonly found in protein aggregates, such as β-sheets, would represent strong candidates for such compounds and are therefore desirable.

The invention relates to a method for in-vitro amplification of NK cells, and in particular relates to a method for massive in-vitro amplification of NK cells, wherein the method comprises the following steps of: a, inoculating a peripheral blood mononuclear cell in a CD3McAb and CD226McAb pre-coated culture bottle for coculture; b, adding 1L-2 and 1L-18, coculturing for 72hours to stimulate amplification of NK cells; c, transferring the NK cells, K562 cells after lethal treatment and a serum-free medium containing 1L-2 and 1L-18 in a cell culture bag for coculture; and d, collecting the NK cells. According to the method for in-vitro amplification of the NK cells, two antibodies CD3McAb and CD226McAb are simultaneously coated, so the cell factor synthesis and ADCC effect are promoted, and killing toxicity of the NK cells is remarkably improved; the activation and amplification on the NK cells are achieved just by the 1L-2 and 1L-18 cell factors, so the amplification multiple and cell toxicity of the NK cells are guaranteed, and the cost of cell culture is reduced.

The invention discloses a method for preparing graphene oxide with high fluorescent quantum yield, which comprises the following steps of: oxidizing and ultrasonically peeling the graphite sheets serving as a starting raw material to obtain the graphene oxide; performing reflux reaction on the graphene oxide and thionyl chloride under the protection of nitrogen for 24 to 72 hours to obtain the intermediate chlorinated graphene oxide; and reacting the intermediate with excess alkylamine at the temperature of between 60 and 120 DEG C for 24 to 72 hours under the protection of the nitrogen to obtain the graphene oxide modified by the alkylamine. The product has strong blue fluorescent light with the fluorescence efficiency more than or equal to 10 percent, high biocompatibility and low cell toxicity, and can be widely applied to the biomarker and cell imaging.

Compositions and methods for preparing stabilized CSA compositions having reduced agglomeration and increased stability. The compositions have increased efficacy in killing microbes and reduced cytotoxicity to mammals. The compositions include a liquid carrier, micelles formed from an amphiphilic material, and CSA molecules encapsulated by the micelles. The CSA compositions can be formed by blending together a solvent or liquid carrier, a plurality of CSA molecules, and a micelle-forming agent and causing or allowing the micelle-forming agent to form micelles encapsulating at least a portion of the CSA molecules so that no more than 25% of the CSA molecules form agglomerates larger than 1 μm in size. The CSA compositions can be used to treat mammals, such as mammals suffering from microbial diseases or infections.

The invention relates to a medical alloy material, in particular to a uniformly degradable orthopedic implant magnesium alloy material. The orthopedic implant magnesium alloy material comprises the following components in percentage by weight: 0-5% of Gd, 1-5% of Nd, more than 0-2% of Sr, 0-0.5% of Zn, more than 0-1% of Zr and the balance of Mg. Due to the addition of magnesium alloy elements Gd and Nd, the strength and the corrosion resistance of the magnesium alloy are improved. In addition, a small amount of Gd and Nd are better in bio-safety; Sr has the effect of inducing growth of osteoblasts; Zn is a human necessary micronutrient element, and the ductility and the corrosion resistance of the alloy can be improved due to the addition of the Zn; and Zr has the effects of refining crystal grains and improving the strength and the corrosion resistance of the alloy and can enable the magnesium degrading speed to be more uniform, and no cell toxicity exists after a small amount of Zr is added.

The invention relates to a self-solidification biological active material of hemigydrate calcium sulfate base, relative production and application. Wherein, the invention is characterized in that: said material is paste formed by harmony liquid, hemigydrate calcium sulfate / tricalcium silicate composite powder, while their mass ratio is 0.8-1.2:1; said harmony liquid is one of deionized water, analogue humor, inorganic salt solution or inorganic solution; the content of tricalcium silicate in the hemigydrate calcium sulfate / tricalcium silicate composite is 1-50%. The invention can be shaped freely, without cell toxicity, while it can be degraded stepped with adjustable speed, and it can induce the generation of skeleton agustite, with higher activity then calcium sulfate material.

The invention discloses a culturing method of an NK (natural killer) cell. The culturing method comprises the following steps of (1) separating a mononuclear cell from peripheral blood or umbilical cord blood of a human body; (2) inoculating the mononuclear cell into a culture medium suitable for culturing lymphocyte, adding a CD3 monoclonal antibody, recombinant human interleukin 2 and autologous plasma, and culturing for 3 to 5 days; (3) adding the recombinant human interleukin 2 and the autologous plasma, and culturing; (4) harvesting the NK cell. According to the culturing method of the NK cell, the culturing cost is reduced, the amplification multiple and cell toxicity of the NK cell are guaranteed, the operation time is saved, meanwhile the probability of error operation is reduced, the obtaining efficiency of the NK cell is higher, and the safety of the NK cell is better.

The invention discloses a graphene quantum dot nuclear targeting medicine carrying system as well as a preparation method and application thereof. The preparation method comprises the following steps: firstly, sterilizing an aqoeous solution of a graphene quantum dot and an aqoeous solution of an anti-cancer medicine; secondly, mixing the aqoeous solution of the graphene quantum dot and the aqoeous solution of the anti-cancer medicine according to the mass ratio of (5:1)-(50:1) to obtain a medicine carrying system; thirdly, co-cultivating the medicine carrying system and cells, detecting the toxicity of the cells by using an MTT (Methyl Thiazolyl Tetrazolium) method and detecting a medicine loaded into the cells by using a fluorescent microscope. According to the invention, by virtue of the characteristic that the graphene quantum dot has a single-atom planar structure, the graphene quantum dot and a micromolecule anticancer medicine with a polycyclic planar structure are combined by bonds to form the medicine carrying system which can stably exist in the aqoeous solution. The graphene quantum dot has a medicine carrying function; meanwhile, the graphene quantum dot has a special structure, so that the toxicity of the medicine to the cells can be increased. The medicine carrying system has the advantages of lower toxicity, simple preparation method, easiness for implementation and double functions of carrying the medicine and enhancing the toxicity of the medicine to the cells.

The invention relates to polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, a preparation method thereof and application thereof. The preparation method comprises the step of directly condensing carboxyl in the polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine segmented copolymer with amino in polyethyleneimine to form the graft copolymer. The copolymer is a polycation gene carrier, integrates the advantages of polyethylene glycol, Makrolan and polyethyleneimine, and has high transfection efficiency, wherein the highest transfection efficiency to the medium luciferase plasmid of african green monkey kidney cell is 14 times of that of American Invitrogen biological company transfection reagent Lipofetamine<TM>2000, can effectively antagonize the inhibiting effect of blood serum to the transfection, and has less cell toxicity, wherein consistency thereof is not higher than 200 microgramme / ml and cell survival rate is more than 80%.

Preparation of a novel living cell mitochondrion probe based on carbon dots (CDs) is disclosed. A product TPP-CDs is prepared by synthesizing the CDs surfaces of which are provided with amino by adopting citric acid and urea as raw materials through a hydrothermal method, grafting with a triphenylphosphine (TPP) small molecule the tail end of which is provided with carboxyl through an amidation reaction, and separating and purifying by utilization of an aqueous membrane and a glucan G-25 gel column. The mitochondrion probe is simple in preparation method and capable of large-scale production, has good water solubility, good light stability and wide excitation and emission spectrum ranges, and breaks the current situation that mitochondrion probes at present generally are poor in water solubility and liable to fluorescence quenching. In addition, the mitochondrion probe is low in cell toxicity and biological-friendly, and can be successfully used for mitochondrion imaging of living cells.

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

The invention discloses a preparing technique of special pharmacological strontium sustained-release and no-toxicity strontium-containing nano calcium phosphate bioactive cement. It adopts the cement solid phase: the mixed powder of Ca4(PO4)2O, CaHPO4 and SrHPO4 distributed at a certain particle size and prepared in a certain mole ratio and the liquid phase: H3PO4 solution at 0.5-1 mol / l, where the solid-liquid ratio is 1.5-3.0. On physiological conditions, and the final condensate product is strontium-containing acalcerosis hydroxyl phosphorite with a microscopic daisy-petal or bent-stick shaped nano crystal structure. This cement not only has higher mechanical and operable properties, but also sustainedly releases strontium ions with special pharmacological functions, and the result of preliminary cell toxicity test shows it has no toxicity. It has wider application prospect than traditional calcium phosphate cement.

The invention discloses a preparation technology of a PCL / GE (polycaprolactone / gelatin) electrospinning composite stent, and belongs to the technical field of biological tissue engineering stents. The preparation technology sequentially comprises a preparation technology of a PCL / GE nanometer fiber electrospinning film which is made of an artificial cell extracellular matrix (ECM) stent material, a preparation method of an electrospinning film coated with hydroxyapatite crystals, and a building method of the electrospinning composite stent. The preparation technology has the advantages that the electrospinning film coated with the hydroxyapatite crystals and the PCL / GE electrospinning film are combined to form an ECM structure which is similar to natural bone tissues; the prepared electrospinning composite stent has no obvious cell toxicity, the internal stent structure is similar to the ECM of the natural bone tissues, and the outer layer structure can block the invasion of peripheral connective tissues; the biocompatibility is good, and the regeneration of bone tissues can be effectively promoted; a stable environment is provided for the regeneration of new bones, and the structure and function of the ECM of the normal bone tissues can be simulated.

The invention relates to the field of medical technologies, in particular to a lipoic-acid-modified nanometer polypeptide carrier and a preparation method and application thereof.The lipoic-acid-modified nanometer polypeptide carrier is composed of arginine, histidine, lipoic acid and cysteine.A disulfide bond contained in lipoic acid is adopted for cross-linking, a formed polypeptide polymer can be rapidly degraded in cells and will not accumulate in the cells, and arginine and cysteine in polypeptide are in-vivo amino acid and are free of toxic and side effects to the human body.A CCK-8 cell proliferation test shows that the prepared nanometer carrier has low cell toxicity and meanwhile has good capacity of co-delivery of a gene and chemotherapy drugs; the nanometer carrier can specifically enhance the sensitivity of drug-resistant cells to the chemotherapy drugs in breast cancer drug-resistant treatment and promote apoptosis of breast cancer cells, and therefore becomes a targeted, efficient and low-toxicity nanoscale delivery system in breast cancer drug-resistant treatment.

The invention relates to a method for mensurating cytotoxicity of mainstream cigarette smoke. The method is characterized in comprising the following steps: firstly, a cultured cell is directly put to the mainstream cigarette smoke diluted by clean air and is exposed; secondly, the cell is subjected to neutral red staining; according to the situation that the cell is ingested with neutral red, a spectrophotometer of a readable porous culturing plate is utilized to mensurate an absorbance value; and the cell is compared with a contrastive sample exposed in the clean air, thereby judging the toxicity of the mainstream cigarette smoke. The method is based on a testing principle that the cultured cell is directly put to the mainstream cigarette smoke and is exposed; the level for ingesting the neutral red by the cell is in positive proportion to the number of viable cells; when the toxic effect of the mainstream cigarette smoke is larger, the survival cells exposed in the mainstream cigarette smoke is fewer, correspondingly the dye absorption amount is less and the absorbance value is lower. The method can quantitatively evaluate the cytotoxicity of a tested object, has the characteristics of simple operation, high sensitivity and reliable result, and creates a new method for mensurating the cytotoxicity of the mainstream cigarette smoke.

The invention belongs to the field of medicines, and in particular relates to DOTAP-mPEG-PLA nanoparticles, a solution of the nanoparticles, a medicine-carrying compound as well as a preparation method and an application. The invention aims at providing an amphiphilic mPEG-PLA diblock copolymer modified by DOTAP, and a novel biodegradable gene carrier, namely, the DOTAP-mPEG-PLA nanoparticles (DPP nanoparticles for short) is prepared through a self-assembly method. The DPP nanoparticles have good DNA binding capacity, gene plasmids can be effectively guided into cancer cells, and the advantages of high transfection efficiency and low cell toxicity are achieved.

Described is a process for delivering a biologically active compound to a cell by reversibly linking the compound to a membrane active polymer. In particular, polymer-polynucleotide conjugates are described. Methods for reversibly modifying the polymers to decrease cellular toxicity and improve efficacy are provided.

The invention provides a method of a fluorescent star-like polymer which serves as a nucleic acid material carrier and is applied to live culture of cells and insects. A perylene derivative and an analogue thereof are taken as fluorescent nucleotides, and fluorescent star-like polymers which are in different generations and carries cation groups are prepared by adopting a 'divergent method'. The fluorescent star-like polymer has good biocompatibility and low cell toxicity, amino groups with positive charges can be carried at the periphery of a molecule, can enter live culture cells and can be combined with DNA or RNA with negative charges to form a stable complex, and the stable complex is taken as a carrier to carry and protect exogenous nucleic acid to enter live culture cells. Mixture of the carrier and the DNA or RNA is fed in food or injected into a body cavity, the carrier can quickly carry the DNA or RNA to enter cells of a live insect in vivo, and effect exertion of nucleic acid and normal expression of genes interfering insect targets are facilitated, so that insects are abnormal in development until the insects fall ill or die.

The invention provides an anti-infection biological ceramic artificial bone and application thereof. The artificial bone is prepared by the following method that biological ceramics, bioglass sintering auxiliary agents and bonding agents are mixed; the obtained mixture is formed to obtain a composite blank body; the bioglass sintering auxiliary agents are selected from silicate glass and / or phosphate glass; antibacterial ions and bone vascularization promotion ions are mixed in the bioglass sintering auxiliary agents; the antibacterial ions are selected from one or several kinds of materials from silver, gallium, copper and zinc; the bone vascularization promotion ions are selected from one or several kinds of materials from magnesium, strontium, iron, boron, cobalt and lithium; the total amount of substances of oxides of the antibacterial ions and oxides of the bone vascularization promotion ions accounts for 0.1 to 60 percent of the amount of substance of the bioglass sintering auxiliary agents; the mol ratio of the antibacterial ions to the bone vascularization promotion ions is (0.05 to 20):1; the composite blank body is sintered to obtain the biological ceramic artificial bone. The anti-infection biological ceramic artificial bone has the advantages of high intensity and low cell toxicity; the antibacterial ion release speed is controllable; the release time is long.